Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects

NCT00625196 | Completed Phase 1

• 1 other identifier: HZA102940
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

A combination of the corticosteroid GW685698X and the long-acting ß2-agonist GW642444M is being developed for once daily administration for the maintenance treatment of asthma and COPD. GW642444M and GW685698X will be simultaneously co-administered from a single device and compared with GW642444M and GW685698X administered separately in order to determine whether co-administration affects the safety, tolerability, pharmacodynamic and/or pharmacokinetics of either compound in healthy Japanese subjects.

Conditions

Asthma

Keywords

Healthy Japanese volunteers

Outcome Measures

Primary Outcomes (5)

• Maximum heart rate

  over 4 hours after dosing.

• Blood pressure changes

  over 12 hours.

• Electrocardiogram changes

  over 12 hours.

• Change in peak expiry flow rate changes

  over 24 hours.

• Change in serum cortisol concentration changes

  over 24 hours

Secondary Outcomes (4)

• Change in plasma drug concentration (AUC, Cmax, t1/2, tmax)

  over 48 hours after dosing.

• Change in blood potassium levels

  within 4 hours of drug dosing.

• Mean heart rate

  over 4 hours after dosing

• Plasma concentrations and derived pharmacokinetic parameters (AUC, Cmax,t½, tmax) for GW685698X, GW642444 and the GW642444 inactive metabolites GW630200 and GSK932009

  over 48 hours after dosing

Study Arms (4)

Subjects receiving fluticasone foroate/ vilanterol

EXPERIMENTAL

Eligible subjects will receive single dose of fluticasone foroate/ vilanterol combination treatment 800 micrograms/ 50 micrograms administered using a novel powder inhaler. There will be a washout period of 7 to 10 days between treatments.

Drug: Fluticasone foroate/ vilanterol; Drug: Fluticasone foroate; Drug: Vilanterol

Subjects receiving fluticasone foroate

ACTIVE COMPARATOR

Eligible subjects will receive single dose of fluticasone foroate 800 micrograms administered using a novel powder inhaler.

Drug: Fluticasone foroate

Subjects receiving vilanterol

ACTIVE COMPARATOR

Eligible subjects will receive single dose of vilanterol 50 micrograms administered using a novel powder inhaler.

Drug: Vilanterol

Subjects receiving placebo

PLACEBO COMPARATOR

Eligible subjects will receive single dose of placebo administered using a novel powder inhaler.

Drug: Placebo

Interventions

Fluticasone foroate/ vilanterol DRUG

Fluticasone foroate/ vilanterol 800 micrograms/ 50 micrograms will be available as dry powder inhaler.

Subjects receiving fluticasone foroate/ vilanterol

Fluticasone foroate DRUG

Fluticasone foroate 800 micrograms will be available as dry powder inhaler.

Subjects receiving fluticasone foroate; Subjects receiving fluticasone foroate/ vilanterol

Vilanterol DRUG

Vilanterol will be available as dry powder inhaler.

Subjects receiving fluticasone foroate/ vilanterol; Subjects receiving vilanterol

Placebo DRUG

Placebo will be supplied as dry powder inhaler.

Subjects receiving placebo

Eligibility Criteria

• Age: 20 Years - 60 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male adults aged between 20 and 60 years inclusive
• Healthy as determined by a responsible physician, based on a medical evaluation including history, physical examination, laboratory tests, and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator considers that the finding will not introduce additional risk factors and will not interfere with the study procedures.
• Male subjects must use double-barrier (condom/spermicide) birth control methods or abstain from sexual intercourse with female partners who are pregnant, lactating, or able to bear children in addition to any birth control method the female partner is using, from the first dose of study medication until 90 days after the last dose of study medication.
• Japanese ethnic origin (defined as having been born in Japan with four ethnic Japanese grandparents and able to speak Japanese)
• Body weight ≥ 45 kg and body mass index within the range of 18-28 kg/m2 inclusive.
• No significant abnormality on 12-lead ECG at screening, including the following specific requirements:
• Ventricular rate ≥ 45 beats per minute
• PR interval ≤ 210msec
• Q waves \< 30msec (up to 50 ms permitted in lead III only)
• QRS interval to be ≥ 60msec and ≤ 120msec
• The waveforms must enable the QT interval to be clearly defined
• QTc interval must be \< 450msec (QTcB or QTcF; machine or manual reading) based on a single ECG value, or an average from three ECGs obtained over a brief recording period
• No significant abnormality on the Holter ECG at screening.
• FEV1 ≥90% predicted and FEV1 / FVC ratio ≥ 0.7 at screening
• Subjects who are current non- smokers who have not used any tobacco products in the 12 month period preceding the screening visit and have a pack history of \< 5 pack years

You may not qualify if:

• As a result of medical interview, physical examination or screening investigations, the principle investigator or delegate physician deems the subject unsuitable for the study. Subjects must not have a systolic blood pressure above 145 mmHg or a diastolic pressure above 85 mmHg unless the Investigator confirms that it is satisfactory for their age.
• The subject has been treated for or diagnosed with depression within six months of screening or has a history of significant psychiatric illness.
• Subjects who have suffered an upper or lower respiratory tract infection within 4 weeks of the screening visit.
• Liver function tests (AST, ALT or ALP) greater than 1.5 of the upper limit of laboratory reference range.
• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
• History of milk protein allergy.
• The subject has taken prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is the longer) prior to the first dose of study medication, unless in the opinion of the Investigator and Sponsor the medication will not interfere with the study procedures or compromise subject safety.
• The subject has taken oral corticosteroids less than 8 weeks before the screening visit
• The subject has taken inhaled, intranasal or topical steroids less than 4 weeks before the screening visit
• History of alcohol/drug abuse or dependence within 12 months of the study
• Abuse of alcohol defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males) or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). One unit is equivalent to a 285mL glass of full strength beer or 425mL schooner of light beer or 1 (30mL) measure of spirits or 1 glass (100mL) of wine
• The subject has participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication.
• Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
• The subject has donated a unit (450mL) of blood within the previous 16 weeks or intends to donate within 16 weeks after completing the study.
• A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Randwick, New South Wales, 2031, Australia

Location

Related Publications (1)

• Nakahara N, Wakamatsu A, Kempsford R, Allen A, Yamada M, Nohda S, Hirama T. The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. Int J Clin Pharmacol Ther. 2013 Aug;51(8):660-71. doi: 10.5414/CP201822.

  PMID: 23735179 BACKGROUND

Related Links

• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
• Results for study HZA102940 can be found on the GSK Clinical Study Register.

MeSH Terms

Conditions

Asthma

Interventions

vilanterol

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 19, 2008
• First Posted: February 28, 2008
• Study Start: February 27, 2008
• Primary Completion: May 6, 2008
• Study Completion: May 6, 2008
• Last Updated: August 21, 2017

Record last verified: 2017-08

Data Sharing

• IPD Sharing: Will share

Locations

AU (1)